TATA-box binding protein associated factor 12Genealiases: TAF2J · TAFII20
Q-omics provides the consensus-scored TAF12 profile across patient tissues and cancer cell-line models. TAF12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TAF12 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TAF12 protein abundance shows 22,185 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where TAF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF12 survival associations across molecular data types. TAF12 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF12 RNA expression–survival associations across cancer types. High TAF12 expression shows unfavorable associations in KIRP, ACC, KICH, LIHC and LGG, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TAF12 RNA expression.
This table summarizes TAF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF12 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, LUAD and BLCA. The HNSC box plot shows higher TAF12 RNA expression in tumor versus normal tissue (log2 FC = +1.105, t-test p < 0.001).
This table shows molecular features associated with TAF12 in patient tissues and cancer cell lines. In patient samples, TAF12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
